Malaria vaccine took 30 years and it’s still a work in progress

After more than three decades of work and almost $1-billion of investment, GlaxoSmithKline and its partners are ready to deploy a vaccine for malaria, the mosquito-borne disease that kills almost half a million people each year. The vaccine, developed with the nonprofit organisation PATH, comes at a critical time and marks a milestone in the battle against the parasite that causes malaria. But the injection is more pioneer than panacea: it prevented only about four in ten malaria cases among children who received four doses in a large study.